既有过硬的产品,又有不俗的业绩,这家 中药 饮片巨头为何多次冲刺IPO未果?四川新荷花中药饮片股份有限公司(下称“新荷花”)近日向港交所递交招股书,在谋划A股上市多年未果后正式转战港股。招股书显示,新荷花是中国领先且最大的中药饮片产品供应商之一。按2023年中药饮片产品收入计算,公司在中国排名第2位。新荷花一边寻求上市,一边保持了营收增长,2023 年营收为 11.46 亿元,较 2022 年增长...
Source Link既有过硬的产品,又有不俗的业绩,这家 中药 饮片巨头为何多次冲刺IPO未果?四川新荷花中药饮片股份有限公司(下称“新荷花”)近日向港交所递交招股书,在谋划A股上市多年未果后正式转战港股。招股书显示,新荷花是中国领先且最大的中药饮片产品供应商之一。按2023年中药饮片产品收入计算,公司在中国排名第2位。新荷花一边寻求上市,一边保持了营收增长,2023 年营收为 11.46 亿元,较 2022 年增长...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.